20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- JMP Securities has downgraded PLx Pharma Inc (NASDAQ:PLXP) to Market Perform from Market Outperform as the company explores strategic alternatives.
- PLX Pharma reported 2Q FY22 financial results below expectations, primarily due to lower-than-expected Vazalore sales this quarter ($0.5 million vs. JMP/ consensus estimate of $3.3 million/$3.6 million, respectively).
- The management pointed to multiple macro headwinds impacting the launch, JMP writes.
- The company disclosed that it is exploring strategic options and has implemented a more cost-conscious marketing plan, focused on virtual and digital activities and scaled-down in-person detailing.
- The company commented that the current inflationary environment had put pressure on consumer adoption and increased price sensitivity.
- JMP adjusted the model, including lowering Vazalore sales estimates in 2H 2022 and beyond.
- Vazalore sales estimate supports upside from the current valuation, but JMP believes that the current strategic review process places substantial uncertainty.
- The stock is currently trading at ~1.3x cash, which the analyst views as a fair value until more visibility on strategic alternatives or the macro environment.
- Price Action: PLXP shares are down 14.60% at $1.40 during the market session on the last check Monday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!